...
首页> 外文期刊>Radiology >Initial staging of differentiated thyroid carcinoma: continued utility of posttherapy 131I whole-body scintigraphy.
【24h】

Initial staging of differentiated thyroid carcinoma: continued utility of posttherapy 131I whole-body scintigraphy.

机译:分化型甲状腺癌的初步分期:治疗后131I全身闪烁显像的继续应用。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

PURPOSE: To retrospectively compare pretherapy iodine 123 ((123)I) and posttherapy iodine 131 ((131)I) sodium iodide whole-body scintigraphy of patients with newly diagnosed differentiated thyroid cancer to determine if there is significant and clinically relevant discordance of nonphysiologic iodide-avid foci (IAFs) between the two examinations. MATERIALS AND METHODS: This study was approved by the Institutional Review Board, the requirement for informed consent was waived, and the study complied with HIPAA. The authors identified 108 patients (88 women, 20 men; age range, 16-86 years; mean, 47.5 years; 45 patients younger than 45 years, 63 patients 45 years and older) who previously had undergone total or near-total thyroidectomy for differentiated thyroid carcinoma. Each patient had undergone a pretherapy ( 123)I whole-body scan followed by a posttherapy ( 131)I whole-body scan. The number and location of IAFs were recorded on both scans. Data were compared by using a Wilcoxon signed rank test for paired data and assessed clinical relevance based on changes in tumor staging. RESULTS: Posttherapy ( 131)I whole-body scans revealed additional IAFs outside the thyroid bed not detected on pretherapy ( 123)I scans in 21 (19%, P < .001) of 108 patients. Nineteen (90%) of these 21 had IAFs in new locations (P < .001), with tumor upstaging of 11 (59%, 10% of total) of those 19 patients; six (55%, 6% of total) of those 11 had scintigraphic patterns consistent with unsuspected metastatic disease. Concordant scintigraphic patterns were observed in 87 (81%) of 108. CONCLUSION: In patients with newly diagnosed differentiated thyroid cancer who had undergone thyroidectomy and ( 131)I ablation, posttherapy ( 131)I whole-body scintigraphy revealed new IAFs in 18% and clinical upstaging occurred in 10% of patients compared with pretherapy ( 123)I whole-body scintigraphy. Therefore, posttherapy ( 131)I whole-body scintigraphy provides incremental clinically relevant information as it helps to establish the true extent ofIAFs and may contribute to altering of staging.
机译:目的:回顾性比较新诊断的分化型甲状腺癌患者的治疗前碘123((123)I)和治疗后碘131((131)I)碘化钠全身显像,以确定非生理学上是否存在重大且与临床相关的不一致两次检查之间的碘化物-avid病灶(IAF)。材料与方法:该研究获得机构审查委员会的批准,免除知情同意的要求,并且该研究符合HIPAA。作者确定了先前曾接受全甲状腺或全甲状腺切除术的108例患者(88例女性,20例男性;年龄范围16-86岁;平均47.5岁; 45岁以下的患者小于45岁,63岁的患者45岁及以上)。分化型甲状腺癌。每位患者均接受了治疗前(123)I全身扫描,然后接受了治疗后(131)I全身扫描。在两次扫描中都记录了IAF的数量和位置。使用Wilcoxon符号秩和检验对数据进行配对数据比较,并根据肿瘤分期的变化评估临床相关性。结果:治疗后(131)I全身扫描显示,在108例患者中有21例(19%,P <.001)中未在治疗前(123)I扫描中发现甲状腺外的IAF。在这21例患者中,有19例(90%)在新的位置出现了IAF(P <.001),在这19例患者中,有11例发生了肿瘤升级(占59%,占总数的10%)。这11人中有6人(占总数的5%,占总数的6%)的闪烁显像模式与未曾怀疑的转移性疾病一致。在108名患者中,有87名(81%)观察到一致的闪烁显像模式。结论:在接受新的甲状腺分化和(131)I消融治疗的新诊断分化型甲状腺癌患者中,治疗后(131)I全身闪烁显露了18%的新IAF。与治疗前相比,有10%的患者发生了临床升级(123)I全身闪烁显像。因此,治疗后(131)I全身闪烁显像技术提供了增量的临床相关信息,因为它有助于确定IAF的真实范围,并可能有助于分期的改变。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号